SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 29 Issue: 2 Special Issue

Latest updates on chronic delta hepatitis

Kendal Yalçın
Elif Tuğba Tuncel
Feyza Gündüz
Pages
—
Publication Date
2016-08-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In contrast, the controlof HBV infecion does not seem to change the natural history ofHDV related disease.Keywords: Delta hepatitis, Treatment, Prognosis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The hepatitis D virus was shown for the first time in 1977 byRizzetto and friends.
📊
Key Findings & Data:The HDV genome and the cloning ofsequence were made in 1986.
💡
Conclusion & Impact:In contrast, the controlof HBV infecion does not seem to change the natural history ofHDV related disease.Keywords: Delta hepatitis, Treatment, Prognosis
🔬Design:Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatit D · Tedavi · Prognoz

Abstract

The hepatitis D virus was shown for the first time in 1977 byRizzetto and friends. The HDV genome and the cloning ofsequence were made in 1986. HDV is the first animal virus withcircular RNA genome which is seen only in plant viruses. HDVis an RNA virus with the known smallest viral genome in animalviruses. It is classified as Deltavirus genius depending on the typeof virus by ICTV in 1996. HDV is classified as the sole example ofdelta virus in this genus.Chronic delta hepatitis is the least common form of chronicviral hepatitis due to hepatotropic viruses. In contrast, the virusis highly pathogenic and can cause serious consequences. Today,prevalance of delta hepatitis has been shown to decrease. However,the delta hepatitis continues to be an important health problem insome parts of the world. In our country, especially in Eastern andSoutheastern Anatolia, hepatitis D is a serious and important healthproblem and still maintains its importance as a health problem. InTurkey, still there is a significant number of patients with HDVinfection despite a documented decrease in HDV infection.The recommended treatment for chronic HDV infection in thecurrent guidelines is the treatment with peginterferon alfa givenonce a week for 48 weeks. Treatment is indicated for patients whohas compensated disease with active infection. In patients withadvanced form of disease, the expected benefits of the peginterferonmust be well balanced against the potential side effects and lowresponse rate. An oral antiviral can be recommended in patientswho has high levels of serum HBV DNA. In contrast, the controlof HBV infecion does not seem to change the natural history ofHDV related disease.Keywords: Delta hepatitis, Treatment, Prognosis

Özet

The hepatitis D virus was shown for the first time in 1977 byRizzetto and friends. The HDV genome and the cloning ofsequence were made in 1986. HDV is the first animal virus withcircular RNA genome which is seen only in plant viruses. HDVis an RNA virus with the known smallest viral genome in animalviruses. It is classified as Deltavirus genius depending on the typeof virus by ICTV in 1996. HDV is classified as the sole example ofdelta virus in this genus.Chronic delta hepatitis is the least common form of chronicviral hepatitis due to hepatotropic viruses. In contrast, the virusis highly pathogenic and can cause serious consequences. Today,prevalance of delta hepatitis has been shown to decrease. However,the delta hepatitis continues to be an important health problem insome parts of the world. In our country, especially in Eastern andSoutheastern Anatolia, hepatitis D is a serious and important healthproblem and still maintains its importance as a health problem. InTurkey, still there is a significant number of patients with HDVinfection despite a documented decrease in HDV infection.The recommended treatment for chronic HDV infection in thecurrent guidelines is the treatment with peginterferon alfa givenonce a week for 48 weeks. Treatment is indicated for patients whohas compensated disease with active infection. In patients withadvanced form of disease, the expected benefits of the peginterferonmust be well balanced against the potential side effects and lowresponse rate. An oral antiviral can be recommended in patientswho has high levels of serum HBV DNA. In contrast, the controlof HBV infecion does not seem to change the natural history ofHDV related disease.Keywords: Delta hepatitis, Treatment, Prognosis

🔖

Cite This Article

Yalçın, K., Tuncel, E. T., Gündüz, F. (2016). Latest updates on chronic delta hepatitis. Marmara Medical Journal, Volume: 29 Issue: 2 Special Issue. https://doi.org/10.5472/MMJsi.2901.10

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (135)

  1. Rizzetto M. Critical care options. In: Afdhal NH, Zeuzem S
  2. editors. Clinical Care Options, Hepatitis, Practice, Hepatitis
  3. Delta virus. Last Reviewed: 6/23/14 (What’s New).
  4. Taylor JM. Replication of the hepatitis delta virus RNA
  5. genome. Adv Virus Res 2009;74:103-21.
  6. Greco-Stewart VS, Schissel E, Pelchat M. The hepatitis
  7. delta virus RNA genome interacts with the human RNA
  8. polymerases I and III. Virology 2009;386:12-5.
  9. World Health Organization. Hepatitis B fact sheet 204
  10. (updated July 2013). Available at: http://www.who.int/
  11. mediacentre/factsheets/fs204/en/index.html. Accessed June
  12. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta
  13. virus. Lancet 2011;378:73-85.
  14. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin
  15. Liver Dis 2012;32:211-9.
  16. Farci P. Delta hepatitis: an update. J Hepatol 2003;39(suppl
  17. S212-S219.
  18. Genné D, Rossi I. Hepatitis delta in Switzerland: a silent
  19. epidemic. Swiss Med Wkly 2011 Mar 18.
  20. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB.
  21. Italian Hospitals’ Collaborating Group. Evolving clinical
  22. landscape of chronic hepatitis B: a multicenter Italian study. J
  23. Med Virol 2009;81:1999-2006.
  24. Değertekin H, Yalcin K, Yakut M, Yurdaydin C.
  25. Seropositivity for delta hepatitis in patients with chronic
  26. hepatitis B and liver cirrhosis in Turkey: a meta-analysis.
  27. Liver Int 2008;28:494-8.
  28. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y
  29. Yalniz M. Prevalence of hepatitis delta virus (HDV) infection
  30. in chronic hepatitis B patients in eastern Turkey: still a serious
  31. problem to consider. J Viral Hepat 2011;18:518-24.
  32. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis
  33. delta virus infection in acute and chronic liver diseases in
  34. Turkey: An analysis of clinical studies. Turk J Gastroenterol
  35. Yalçın K, Yalçın S, Büyükbayram H, et al. Kronik HDV
  36. infeksiyonlu hastalarda serum HBV DNA, HDV RNA
  37. düzeyleri ve histolojik bulguların hastalığın klinik evreleriyle ilişkisi: prospektif klinik çalışma. 25. Ulusal Gastroenteroloji
  38. Haftası, 2008.
  39. Yalçın K, Değertekin H. Etiology and clinical aspects
  40. of liver cirrhosis in Diyarbakır. National congress of
  41. Gastroenterology, Turkey, 2002.
  42. Bonino F, Caporaso N, Dentico P, et al. Familiar clustering
  43. and spreading of hepatitis delta virus infection. J Hepatol
  44. Wu JC, Chen CM, Sheen IJ, et al. Evidence of transmission
  45. of hepatitis D virus to spouses from sequence analysis of the
  46. viral genome. Hepatology 1995;226:1656-60.
  47. Rosenblum L, Darrow W, Witte J, et al. Sexual practices
  48. in the transmission of hepatitis B virus and prevalence of
  49. hepatitis delta virus infection in female prostitutes in the
  50. United States. JAMA 1992;267:2477-81.
  51. Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D
  52. virus biology and disease. Prog Liver Dis 1994;12:157-75.
  53. Dény P. Hepatitis delta virus genetic variability: from
  54. genotypes I, II, III to eight major clades? Curr Top Microbiol
  55. Immunol 2006;307:151-71.
  56. Shakil AO, Hadziyannis S, Hoofnagle JH, et al. Geographic
  57. distribution and genetic variability of hepatitis delta virus
  58. genotype I. Virology 1997;234:160-7.
  59. Alvarado-Mora MV, Romano CM, Gomes-Gouvêa MS
  60. Gutierrez MF, Carrilho FJ, Pinho JR. Dynamics of hepatitis
  61. D (delta) virus genotype 3 in the Amazon region of South
  62. America. Infect Genet Evol 2011;11:1462-8.
  63. Rizzetto M. Hepatitis D: thirty years after. J Hepatol
  64. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis
  65. B virus infection: relation of age to the clinical expression
  66. of disease and subsequent development of the carrier state. J
  67. Infect Dis 1985;151:599-603.
  68. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.
  69. Hepatology 2009;50:661-2.
  70. Negro F, Rizzetto M. Diagnosis of hepatitis delta virus
  71. infection. J Hepatol 1995;22(1 suppl):136-9.
  72. Smedile A, Niro MG, Rizzetto M. Detection of serum HDVRNA
  73. by RT-PCR. Methods Mol Med 2004;95:85-93.
  74. Le Gal F, Gordien E, Affolabi D, et al. Quantification of
  75. hepatitis delta virus RNA in serum by consensus real-time
  76. PCR indicates different patterns of virological response to
  77. interferon therapy in chronically infected patients. J Clin
  78. Microbiol 2005;43:2363-9.
  79. Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative
  80. longitudinal evaluations of hepatitis delta virus RNA and
  81. hepatitis B virus DNA shows a dynamic, complex replicative
  82. profile in chronic hepatitis B and D. J Hepatol 2010;52:658-
  83. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a
  84. novel quantitative hepatitis D virus (HDV) RNA assay using
  85. the Cobas TaqMan platform to study HDV RNA kinetics. J
  86. Clin Microbiol. 2010;48:2022-9.
  87. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int
  88. Fattovich G, Giustina G, Christensen E, et al. Influence of
  89. hepatitis delta virus infection on morbidity and mortality
  90. in compensated cirrhosis type B. The European Concerted
  91. Action on Viral Hepatitis (Eurohep). Gut 2000;46:420-6.
  92. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence
  93. of hepatitis delta virus (HDV) infection in South London. J
  94. Med Virol 2008;80:277-82.
  95. Ji J, Sundquist K, Sundquist J. A population-based study of
  96. hepatitis D virus as potential risk factor for hepatocellular
  97. carcinoma. J Natl Cancer Inst 2012;104:790-2.
  98. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J
  99. Viral Hepat 2005;12:2-9.
  100. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon
  101. therapy with or without ribavirin in chronic delta hepatitis.
  102. Antivir Ther 2005;10:721-6.
  103. Calle Serrano B, Manns MP, Wedemeyer H. Hepatitis delta
  104. and HIV infection. Semin Liver Dis 2012;32:120-9.
  105. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of
  106. peginterferon alpha-2b in chronic hepatitis delta: relevance
  107. of quantitative RT-PCR for follow-up. Hepatology
  108. Mederacke I, Yurdaydin C, Dalekos GN, et al. Anti-HDV
  109. immunoglobulin M testing in hepatitis delta revisited
  110. correlations with disease activity and response to pegylated
  111. interferon-α2a treatment. Antivir Ther 2012;17:305-12.
  112. Di Martino V, Thevenot T, Colin JF, et al. Influence of
  113. HIV infection on the response to interferon therapy and the
  114. long-term outcome of chronic hepatitis B. Gastroenterology
  115. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with
  116. chronic hepatitis B: updated recommendations from the HIVHepatitis
  117. B Virus International Panel. AIDS 2008;22:1399-
  118. Samuel D, Zignego AL, Reynes M, et al. Long-term
  119. clinical and virological outcome after liver transplantation
  120. for cirrhosis caused by chronic delta hepatitis. Hepatology
  121. Burra P, Germani G, Adam R, et al. Liver transplantation
  122. for HBV-related cirrhosis in Europe: an ELTR study on
  123. evolution and outcomes. J Hepatol 2013;58:287-96.
  124. Lamers MH, Kirgiz ÖÖ, Heidrich B, Wedemeyer H, Drenth
  125. JP. Interferon-α for patients with chronic hepatitis delta: a
  126. systematic review of randomized clinical trials. Antivir Ther
  127. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy
  128. of prenylation inhibitors against hepatitis delta virus. Clin
  129. Invest 2003;112:407-14.
  130. Chang J, Taylor JM. Susceptibility of human hepatitis
  131. delta virus RNAs to small interfering RNA action. J Virol
  132. Fiedler M, Kosinska A, Schumann A, et al. Prime/boost
  133. immunization with DNA and adenoviral vectors protects
  134. from hepatitis D virus (HDV) infection after simultaneous
  135. infection with HDV and woodchuck hepatitis virus. J Virol